<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01845103</url>
  </required_header>
  <id_info>
    <org_study_id>PLT1101.003-M</org_study_id>
    <nct_id>NCT01845103</nct_id>
  </id_info>
  <brief_title>The PEARL 8.0 Post-Approval Study</brief_title>
  <official_title>Post-Approval Study of the PEARL 8.0 Handpiece for Transmyocardial Revascularization (TMR) With the Cardiogenesis Holmium:YAG Laser System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective single arm study of the Cardiogenesis PEARL 8.0 Handpiece Delivery
      System. The purpose of this study is to demonstrate that the 30 day mortality rate among
      patients who are treated with this device is less than the historical rate plus a
      non-inferiority margin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective single arm study of the Cardiogenesis PEARL 8.0 Handpiece Delivery
      System. The PEARL 8.0 Handpiece allows the TMR laser energy to be directed at the heart
      through a small port up to 8 mm in size. The purpose of this study is to demonstrate that the
      30 day mortality rate among patients who receive this device is less than the historical rate
      plus a non-inferiority margin. In a recent study of 34 patients treated with the PEARL 8.0
      device, 3 (8.8%) experienced 30 day mortality. Among 132 patients in the original PMA trial
      treated with the SoloGrip III Handpiece, a similar device delivering identical energy, the 30
      day mortality rate was 5.3% (7/132). In the Post-Approval Study of the SoloGrip III
      Handpiece, 2/72 prospectively enrolled patients died within the first 30 days. Therefore, the
      weighted average of the Pre-market and post-market studies has been calculated (4.4%) and
      will serve as the historical rate.

      This trial will be monitored for success and futility according to a Bayesian adaptive
      design. Based on prior history, we assume patients will be accrued at the rate of
      approximately 1 patient per month and therefore, 30 day mortality will be known for all
      currently enrolled patients at the time each new patient is enrolled.

      The success stopping boundaries for this study are 0/10 and 1/22. Thus, if no deaths are
      observed among the first 10 patients, the study will stop for success. If 1 death is observed
      among the first 10 patients, the study will continue to enroll. If among the first 22
      patients, only 1 death is observed (there are no additional deaths), the study will stop for
      success. At any time, if 2 or more deaths are observed, the study will stop for futility.

      A secondary objective is to assess the effect of channel number on the 30 day mortality rate
      to justify the labeling claims that the risk for early post-operative (30 day) mortality is
      associated with an increased number of channels, and not the function of the operation or
      device.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to the product being discontinued
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Coronary and Cerebrovascular Events (MACCE)</measure>
    <time_frame>30 day</time_frame>
    <description>MACCE includes:
Cardiac related death, CVA, Myocardial Infarction, Serious arrhythmia, CHF</description>
  </secondary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Class IV Angina</condition>
  <eligibility>
    <study_pop>
      <textblock>
        A minimum of two and a maximum of five study sites will be selected for participation. The
        sites (surgeons) will be selected first from those that participated in the PEARL Study TMR
        05-001. If additional sites are required, selection will be made for the sites (surgeons)
        to be familiar with TMR and thoracoscopic surgery. Sites will be asked to offer all
        patients eligible for stand-alone thoracoscopic TMR, who meet the inclusion/exclusion
        criteria, the opportunity to participate in the current study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Class IV angina (according to Canadian Cardiovascular Society Angina Scale)

          -  Ejection Fraction &gt; 30%

          -  Patients with regions of myocardium in the distal two-thirds of the left ventricle
             with reversible ischemia and who are not eligible for direct coronary
             revascularization (e.g., CABG or PTCA).

          -  Patients amenable to thoracoscopic TMR.

        Exclusion Criteria:

          -  Age less than18-years

          -  Pregnant or nursing mothers

          -  Unable to undergo a surgical procedure or general anesthesia

          -  Hepatic disease, renal failure, cancer or major infection

          -  Severely unstable angina (un-weanable from intravenous anti-anginals for 48- hours)

          -  Patients with mechanical/prosthetic heart valves

          -  Myocardial ischemia limited to the right ventricular wall

          -  Q-Wave myocardial infarction within three (3) weeks prior to the procedure

          -  Non Q-Wave myocardial infarction within two (2) weeks prior to the procedure

          -  Requires anticoagulation medications or has other hemorrhagic propensity

          -  Severe arrhythmia within one week prior to the procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott B Capps, MS</last_name>
    <role>Study Director</role>
    <affiliation>CryoLife, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sutter Institute for Medical Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2013</study_first_submitted>
  <study_first_submitted_qc>April 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <results_first_submitted>August 28, 2015</results_first_submitted>
  <results_first_submitted_qc>August 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2015</results_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ANGINA</keyword>
  <keyword>Thoracoscopic</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PEARL 8.0</title>
          <description>Received TMR with PEARL 8.0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PEARL 8.0</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mortality</title>
        <time_frame>30 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PEARL 8.0</title>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Coronary and Cerebrovascular Events (MACCE)</title>
        <description>MACCE includes:
Cardiac related death, CVA, Myocardial Infarction, Serious arrhythmia, CHF</description>
        <time_frame>30 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PEARL 8.0</title>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Coronary and Cerebrovascular Events (MACCE)</title>
          <description>MACCE includes:
Cardiac related death, CVA, Myocardial Infarction, Serious arrhythmia, CHF</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PEARL 8.0</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Adverse Event required hospitalization</sub_title>
                <description>It was noted that this serious adverse event was not cardiac, procedural or device related.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Site and Investigator agree not to publish or present results prior to Sponsor's final report, but in no event shall Site or Investigator be restricted after the expiration of 12m from Project completion. Publication or disclosure made by Site or Investigator shall not contain Sponsor Confidential Information (CI) and text shall be submitted for Sponsor CI review and comment 30d prior to submission or disclosure and can be deferred, not exceeding 90d for the Sponsor to protect its rights in CI.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Capps, MS/ Vice President, Clinical Research</name_or_title>
      <organization>CryoLife, Inc.</organization>
      <phone>800-438-8285</phone>
      <email>clinicaltrialregistration@cryolife.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

